<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04724096</url>
  </required_header>
  <id_info>
    <org_study_id>20MP001</org_study_id>
    <nct_id>NCT04724096</nct_id>
  </id_info>
  <brief_title>Evaluation of OE-MRI in Patients With H&amp;N Cancer</brief_title>
  <official_title>Evaluation of Oxygen Enhanced Magnetic Resonance Imaging for Identification of Hypoxia Induced Resistant Tumours in Patients With Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nottingham University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nottingham University Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the use of oxygen enhanced MRI scanning in a cohort of patients with head and&#xD;
      neck squamous cell carcinomas to identify areas of hypoxia with tumours and relate this to&#xD;
      treatment outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oxygen-enhanced MRI (OE-MRI) is a technique being actively investigated for imaging hypoxia&#xD;
      within cancer tissues. Preliminary clinical data demonstrates the feasibility of using this&#xD;
      methodology to study patients with head and neck squamous cell carcinoma (HNSCC). The&#xD;
      investigators wish to investigate using this methodology to identify hypoxic subvolumes&#xD;
      within HNSCC that may have greater resistance to standard radiotherapy treatment and&#xD;
      investigate the association of such hypoxic regions with treatment outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with areas detected within tumours of the head and neck area that have measurable hypoxia using OE-MRI technique.</measure>
    <time_frame>2 years</time_frame>
    <description>Feasibility of OE-MRI scans to detect hypoxic areas within tumours in patients with head and neck squamous cell carcinomas</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Association with treatment failure</measure>
    <time_frame>2 years</time_frame>
    <description>Test predictive value of OE-MRI to identify patients with the highest risk of treatment failure and provide data to allow a power calculation for a larger future trial of the predictive power of OE-MRI for treatment outcomes in head and neck cancer treated with radiotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumour perfusion</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of routinely used diagnostic MRI images to identify non-perfused parts of tumours in combination with oxygen maps</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Non-patient volunteers</arm_group_label>
    <description>5 non-patient volunteers for testing of protocol to allow for the ascertaining of good quality data prior to the scanning of patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>50 patients to be scanned with the oxygen enhanced MRI scan protocol prior to definitive curative intent therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Oxygen Enhanced MRI scan</intervention_name>
    <description>Dynamic MRI scanning switching from breathing room air to high concentration oxygen part way through the scan.</description>
    <arm_group_label>Non-patient volunteers</arm_group_label>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        5 non-patient volunteers. 50 patients from Nottingham University Hospitals NHS Trust, UK.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Non-patient Volunteer Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years and above&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Patient Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven or strong clinical suspicion of squamous cell carcinoma of the&#xD;
             head and neck&#xD;
&#xD;
          -  Suitable for undergoing radical radiotherapy or chemoradiotherapy according to local&#xD;
             protocols within the head and neck Cancer MDT&#xD;
&#xD;
          -  Age 18 years and above&#xD;
&#xD;
          -  Adequate physical fitness (WHO performance status 0 to 2)&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Non-patient Volunteer Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to MRI scans as identified following completion of the Nottingham&#xD;
             University Hospitals NHS Trust (NUH) standard MR safety screening protocol&#xD;
&#xD;
          -  Severe Chronic Obstructive Pulmonary Disease (COPD) who are at risk of type 2&#xD;
             respiratory failure or require supplemental oxygen&#xD;
&#xD;
          -  Volunteers who are pregnant as identified through the NUH standard MR safety screening&#xD;
             protocol&#xD;
&#xD;
        Patient Exclusion Criteria:&#xD;
&#xD;
          -  Poor physical fitness (WHO performance status greater than 2)&#xD;
&#xD;
          -  Contraindications to MRI scans as identified following completion of the NUH standard&#xD;
             MR safety screening protocol&#xD;
&#xD;
          -  Severe Chronic Obstructive Pulmonary Disease (COPD) who are at risk of type 2&#xD;
             respiratory failure or require supplemental oxygen&#xD;
&#xD;
          -  Patients who are pregnant or breast-feeding (due to IV contrast use in the routine&#xD;
             clinical scan) as identified through the NUH standard MR safety screening protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafal Panek, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nottingham University Hospitals NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rafal Panek, PhD</last_name>
    <phone>0044 115 9249924</phone>
    <phone_ext>62933</phone_ext>
    <email>rafal.panek@nuh.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Boston</last_name>
    <phone>0044 115 9709040</phone>
    <email>researchsponsor@nuh.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Queens Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafal Panek, PhD</last_name>
      <email>rafal.panek@nuh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Alastair McCabe, MSc FRCR</last_name>
      <email>alastair.mccabe@nuh.nhs.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oxygen enhanced MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

